Agios Pharmaceuticals
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2008 |
| Founder | Lewis Cantley, Tak Mak, Craig Thompson |
| Headquarters | Cambridge, Massachusetts , United States |
Area served | Worldwide |
Key people | Brian Goff (CEO) |
| Products | Enasidenib, Ivosidenib, Mitapivat |
| Website | www |
Agios Pharmaceuticals Inc. is an American pharmaceutical firm publicly traded and dedicated to developing treatments for genetically characterized disorders, with a particular emphasis on hemolytic anemias. Established in 2008 by Lewis Cantley, Tak Mak, and Craig Thompson, the company is incorporated in Delaware and operates from its main office in Cambridge, Massachusetts. Agios became a publicly listed company in July 2013.
History
In 2012, a legal dispute arose involving Agios and founder Craig Thompson, concerning allegations of improper use of research originating from the Abramson Family Cancer Research Institute.
Agios entered into a collaboration with Celgene in May 2016 to co-develop metabolic immuno-oncology treatments and licensed the compounds AG-221 and AG-881 to Celgene, with potential licensing fees amounting to $120 million.
Ahead of expected FDA clearance for its inaugural oncology medication enasidenib, Agios secured $250 million through a stock issuance in April 2017.
The company submitted a New Drug Application in December 2017 for ivosidenib, aimed at patients with relapsed or refractory acute myeloid leukemia harboring an IDH1 mutation.
In November 2019, Agios completed a public share offering of 8.25 million units at $31 each, raising roughly $256 million before expenses.
The FDA granted approval in April 2022 to mitapivat, marking it as the first disease-modifying treatment for hemolytic anemia in adults affected by pyruvate kinase deficiency.
Corporate governance
Brian Goff serves as Agios' CEO as of August 2022.
Originally founded as a private entity, Agios transitioned to a public company via its initial public offering in July 2013 and trades on the NASDAQ exchange.